Insmed presents positive patient-reported outcomes and microbiologic data from phase 3 arise study of arikayce® (amikacin liposome inhalation suspension) in patients with ntm lung disease caused by mac at american thoracic society 2024 international conference plenary session

—patients treated with arikayce plus macrolide-based background regimen had meaningfully greater improvements in respiratory symptoms vs. macrolide-based background regimen alone, as measured by the qol-b respiratory domain instrument— — qol-b respiratory domain scores for arikayce patients showed improvement through month 6 and continued to improve through month 7 (1 month off treatment), while improvements in the comparator arm plateaued after month 3 and worsened after month 6 — —microbiologic data presented showed patients in the arikayce-treated arm had numerically greater rates of culture conversion by month 6, and nominally statistically significantly higher rates by month 7, with earlier time to first culture conversion vs.
INSM Ratings Summary
INSM Quant Ranking